OBJECTIVE: Although atrial fibrillation (AF) is the most commonly sustained arrhythmia in adults, few studies have examined the direct treatment cost of AF. METHODS: A Medicare database of a 5% random national sample of all beneficiaries was used to identify patients diagnosed with AF in 2003 and to follow them for 1 year after diagnosis. These patients were matched on a 1:1 basis by age, gender and race. The incremental cost of treating AF was calculated with multivariate regression models adjusting for covariates. RESULTS: In total, 55,260 subjects developed new AF, of which 69% were >or=75 years old, 54% were female and 91% were White. The adjusted mean incremental treatment cost of AF was $14,199 (95% confidence interval $13,201-15,001; p<0.01). Some of this cost was attributable to the incidence of stroke and heart failure at the 1-year post-AF diagnosis. A significantly higher proportion of AF patients experienced stroke (23.1 vs. 13.3%; p<0.01) and heart failure (36.7 vs. 10.4%; p<0.01) compared with Medicare beneficiaries without AF. CONCLUSIONS: Mean incremental direct treatment costs for Medicare beneficiaries with AF were higher than previously reported. Interventions that can reduce the incidence of AF and its complications may also reduce the national economic impact of AF.
OBJECTIVE: Although atrial fibrillation (AF) is the most commonly sustained arrhythmia in adults, few studies have examined the direct treatment cost of AF. METHODS: A Medicare database of a 5% random national sample of all beneficiaries was used to identify patients diagnosed with AF in 2003 and to follow them for 1 year after diagnosis. These patients were matched on a 1:1 basis by age, gender and race. The incremental cost of treating AF was calculated with multivariate regression models adjusting for covariates. RESULTS: In total, 55,260 subjects developed new AF, of which 69% were >or=75 years old, 54% were female and 91% were White. The adjusted mean incremental treatment cost of AF was $14,199 (95% confidence interval $13,201-15,001; p<0.01). Some of this cost was attributable to the incidence of stroke and heart failure at the 1-year post-AF diagnosis. A significantly higher proportion of AFpatients experienced stroke (23.1 vs. 13.3%; p<0.01) and heart failure (36.7 vs. 10.4%; p<0.01) compared with Medicare beneficiaries without AF. CONCLUSIONS: Mean incremental direct treatment costs for Medicare beneficiaries with AF were higher than previously reported. Interventions that can reduce the incidence of AF and its complications may also reduce the national economic impact of AF.
Authors: Angela Sciacqua; Maria Perticone; Giovanni Tripepi; Eliezer J Tassone; Antonio Cimellaro; Deborah Mazzaferro; Giorgio Sesti; Francesco Perticone Journal: Intern Emerg Med Date: 2015-05-05 Impact factor: 3.397
Authors: Wenwen Li; Ajit H Janardhan; Vadim V Fedorov; Qun Sha; Richard B Schuessler; Igor R Efimov Journal: Circ Arrhythm Electrophysiol Date: 2011-10-06
Authors: Qiushi Chen; Nitin Jain; Turgay Ayer; William G Wierda; Christopher R Flowers; Susan M O'Brien; Michael J Keating; Hagop M Kantarjian; Jagpreet Chhatwal Journal: J Clin Oncol Date: 2016-11-21 Impact factor: 44.544
Authors: Steven A Lubitz; Moritz F Sinner; Kathryn L Lunetta; Seiko Makino; Arne Pfeufer; Rosanna Rahman; Caroline E Veltman; John Barnard; Joshua C Bis; Stephan P Danik; Akshata Sonni; Marisa A Shea; Federica Del Monte; Siegfried Perz; Martina Müller; Annette Peters; Steven M Greenberg; Karen L Furie; Charlotte van Noord; Eric Boerwinkle; Bruno H C Stricker; Jacqueline Witteman; Jonathan D Smith; Mina K Chung; Susan R Heckbert; Emelia J Benjamin; Jonathan Rosand; Dan E Arking; Alvaro Alonso; Stefan Kääb; Patrick T Ellinor Journal: Circulation Date: 2010-08-23 Impact factor: 29.690
Authors: Bernd Brüggenjürgen; Stefan Kohler; Nadja Ezzat; Thomas Reinhold; Stefan N Willich Journal: Pharmacoeconomics Date: 2013-03 Impact factor: 4.981